All opportunities to develop and share robust evidence to help us enhance progress towards #elimination of viral #hepatitis should be welcomed! Note special issue of #BMCInfectiousDiseases planned for 2026.
#HepSky #MedSky #GastroSky #IDSky 🧪

‼️ Finally, our post-hoc analysis of the COVACTA trial #COVID19 is out:
--> We showed that the probability of death or UCI stay at day 28 was lower in those with lower Anti-S Ab and treated with tocilizumab vs the same serostatus and placebo
#BMCInfectiousDiseases #IDtwitter